Table.
Patient Characteristics
| Furosemide (n=8) |
Tolvaptan (n=10) |
P-value | |
|---|---|---|---|
| Age (years) | 76.5±6.0 | 73.4±12.3 | 0.52 |
| Male | 6 (75.0) | 7 (70.0) | 0.62 |
| Body weight (kg) | 54.0±7.1 | 58.2±10.6 | 0.37 |
| BMI (kg/m2) | 21.3±3.5 | 23.2±3.2 | 0.28 |
| Clinical scenario (1/2/3/4/5) | 4/2/2/0/0 | 3/6/1/0/0 | 0.70 |
| Baseline (OMI/Myopathy/VHD) | 3/3/2 | 4/5/1 | 0.71 |
| DM | 2 (25.0) | 4 (40.0) | 0.87 |
| HTN | 3 (37.5) | 5 (50.0) | 0.48 |
| HL | 1 (12.5) | 5 (50.0) | 0.12 |
| UCG findings | |||
| LVEF (%) | 47.4±22.0 | 36.5±9.7 | 0.25 |
| LVDd (mm) | 59.3±13.4 | 63.5±8.0 | 0.47 |
| TRPG (mmHg) | 9.9±13.1 | 35.9±20.7 | 0.51 |
| Laboratory data | |||
| Hb | 11.6±2.0 | 11.6±2.6 | 0.98 |
| Hct | 35.8±5.6 | 35.5±7.7 | 0.92 |
| s-Na | 140±3.1 | 138±4.2 | 0.20 |
| s-CRE | 1.32±0.31 | 1.49±0.60 | 0.48 |
| eGFR | 38.2±11.3 | 38.6±12.9 | 0.94 |
| Cystatin C | 1.88±0.28 | 2.01±0.85 | 0.65 |
| BNP | 626.6±508.0 | 478.0±504.4 | 0.57 |
| PRA | 4.24±5.49 | 8.07±7.61 | 0.28 |
| Aldosterone | 26.4±17.9 | 41.4±20.7 | 0.19 |
| u-β2-MG | 529.5±830.3 | 176.0±232.6 | 0.31 |
| u-NAG | 10.7±6.2 | 9.5±5.1 | 0.66 |
| Premedication of dose and duration of furosemide | |||
| Furosemide (mg) | 45±20.0 | 70±27.2 | 0.050 |
| Duration (days) | 612.9±956.1 | 874.6±1,005.3 | 0.60 |
| Drugs | |||
| ACEI | 2 (25.0) | 3 (30.0) | 0.62 |
| ARB | 5 (62.5) | 5 (50.0) | 0.48 |
| β-blocker | 3 (37.5) | 1 (10.0) | 0.21 |
| Insulin | 1 (12.5) | 2 (20.0) | 0.59 |
| Digitalis | 1 (12.5) | 4 (40.0) | 0.23 |
| MRA | 5 (62.5) | 8 (80.0) | 0.38 |
Data given as mean±SD or n (%). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; Hct, hematocrit; HL, hyperlipidemia; HTN, hypertension; LVDd, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; OMI, old myocardial infarction; PRA, plasma renin activity; s-CRE, serum creatinine; s-Na, serum sodium; TRPG, tricuspid regurgitation pressure gradient; u-β2-MG, urine β2-microglobulin; UCG, ultrasound cardiography; u-NAG, urine N-acetyl-β-D-glucosaminidase; VHD, valvular heart disease.